Apollo Endosurgery Inc Gets a Buy Rating from Northland Securities

By Ryan Adsit

In a report released today, Suraj Kalia from Northland Securities assigned a Buy rating to Apollo Endosurgery Inc (NASDAQ: APEN), with a price target of $12. The company’s shares opened today at $6.15.

Kalia observed:

“We note that the ASMBS Statement is not a guarantee of reimbursement for Orbera.”

According to TipRanks.com, Kalia is a 4-star analyst with an average return of 5.4% and a 52.4% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, ReShape Lifesciences Inc, and Obalon Therapeutics Inc.

Apollo Endosurgery Inc has an analyst consensus of Moderate Buy, with a price target consensus of $10.75.

The company has a one-year high of $14.09 and a one-year low of $3.55. Currently, Apollo Endosurgery Inc has an average volume of 239.7K.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APEN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA.